First quarter highlights & strategic overview Financial results 22.0% U.S. Healthcare Solutions segment operating income growth y/y Effective tax rate 23.0% 21.0% Cencora, Inc. First Quarter Fiscal 2024 Earnings Call January 31, 2024 In an effort to provide additional and useful information regarding Cencora's financial results and other financial information as determined by generally accepted accounting principles (GAAP), certain materials presented during this event include non-GAAP information. A reconc ...

Financial Data and Key Metrics Changes - The company reported a revenue increase of 15% year-over-year, reaching over $72 billion in the first quarter [19][70] - Adjusted earnings per share rose by 21% year-over-year [19] - Consolidated gross profit was $2.4 billion, up nearly 13%, with a gross profit margin of 3.31%, a decrease of 7 basis points [28] - Consolidated operating income increased by 21% to $886 million [41] - The effective income tax rate was 21%, compared to 19.1% in the prior year [42] Business Line Data and Key Metrics Changes - The U.S. Healthcare Solutions segment revenue was $65.2 billion, up approximately 16%, driven by strong utilization trends and commercial COVID-19 vaccine sales [44] - The International Healthcare Solutions segment revenue was $7.1 billion, up 7% on a reported basis or 9% on a constant currency basis [48] - The Animal Health business experienced low-double digit revenue growth, with stronger performance in the companion animal segment [6][75] Market Data and Key Metrics Changes - The company noted broad-based strength across human health distribution businesses, benefiting from good volumes and trends in both specialty and full-line distribution [45] - The growth in GLP-1 products contributed significantly to revenue, with a year-over-year increase of $2.2 billion [95] Company Strategy and Development Direction - Cencora is strategically positioning itself at the center of the specialty market, focusing on partnerships with leading innovators in drug development [20][33] - The company is investing in enhancing its logistics capabilities and expanding cryogenic storage to support complex therapies [22][34] - Cencora aims to capitalize on opportunities presented by scientific advancements and the growing needs for commercialization services [64] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing strong performance of the business and raised the fiscal 2024 full-year guidance due to strong first-quarter results [19][50] - The company anticipates continued growth driven by broad-based prescription utilization trends and strong performance in specialty logistics [81][83] - Management acknowledged geopolitical risks but emphasized the resilience of the business model in the face of such challenges [117] Other Important Information - The company ended the quarter with approximately $2.9 billion in cash and generated $763 million in adjusted free cash flow [43] - Cencora published its eighth annual ESG report, highlighting initiatives to ensure resilient operations and support for team members [55][67] Q&A Session All Questions and Answers Question: What are the strengths in the core business driving the operating income growth? - Management highlighted strong performance in commercial COVID-19 vaccines, favorable pharmaceutical utilization trends, and effective expense management as key drivers of the Q1 beat [88] Question: Can you elaborate on the performance of the Global Specialty Logistics business? - Management noted that the Global Specialty Logistics business contributed to strong performance, driven by effective logistics for clinical trials and complex products [92] Question: How is the company addressing the moderation of generic deflation? - Management indicated that there has been a moderation in generic deflation, which has been a smaller headwind, potentially benefiting the company if it continues [94] Question: What is the outlook for the Canadian business? - Management confirmed that the Canadian business, particularly through Innomar, has been strong due to its integrated model and effective market understanding [99] Question: How is the company responding to reduced spending on commercialization from manufacturers? - Management acknowledged the impact of economic cycles but emphasized the long-term trend of investment in life sciences, which the company intends to capitalize on [103] Question: What is the expectation for brand price increases? - Management stated that January price increase activity was in line with expectations, noting that brand inflation is less critical for the company due to its fee-for-service model [105] Question: How does the company view the health of retail customers, particularly independent pharmacies? - Management expressed optimism about the potential adoption of a cost-plus model, indicating a need for improved profitability for community pharmacists [136]

Cencora, Inc. (COR) reported first-quarter fiscal 2024 adjusted earnings per share (EPS) of $3.28, which beat the Zacks Consensus Estimate of $2.86 by 14.7%. The bottom line also improved 21% year over year.GAAP EPS was $2.98, up 27.9% from that reported in the year-ago period.Revenue DetailsRevenues totaled $72.3 billion, up 15% year over year. The top line beat the Zacks Consensus Estimate by 5.1%.Segmental AnalysisU.S. Healthcare SolutionsRevenues in this segment totaled $65.2 billion, up 15.9% on a year ...

Cencora (COR) came out with quarterly earnings of $3.28 per share, beating the Zacks Consensus Estimate of $2.86 per share. This compares to earnings of $2.71 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14.69%. A quarter ago, it was expected that this prescription drug distributor would post earnings of $2.79 per share when it actually produced earnings of $2.86, delivering a surprise of 2.51%.Over the last four quarters, ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Cencora (COR) , which belongs to the Zacks Medical Services industry.This prescription drug distributor has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 2.84%.For the last reported quarter, Cencora came out with earnings of $2.86 pe ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ___________ TO___________ Commission file number 1-16671 CENCORA, INC. (Exact name of registrant as specified in its charter) | Delaware | | | 23-30 ...

Wall Street analysts expect Cencora (COR) to post quarterly earnings of $2.85 per share in its upcoming report, which indicates a year-over-year increase of 5.2%. Revenues are expected to be $68.81 billion, up 9.5% from the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Before a company reveals its earnings, it is vital to take into acco ...

Have you been paying attention to shares of Cencora (COR) ? Shares have been on the move with the stock up 7.5% over the past month. The stock hit a new 52-week high of $221.31 in the previous session. Cencora has gained 6.3% since the start of the year compared to the -1% move for the Zacks Medical sector and the -7% return for the Zacks Medical Services industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus e ...

UNITED STATES ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Indicate by check mark if the registrant is a well-known seasoned issuer (as defined in Rule 405 of the Securities Act). Yes þ No o Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ...

Cencora, Inc. (NYSE:COR) Q4 2023 Results Conference Call November 2, 2023 8:30 AM ET Company Participants Bennett Murphy - SVP, Head IR and Treasury Steve Collis - Chairman, President and CEO Jim Cleary - EVP and CFO Conference Call Participants Lisa Gill - JPMorgan Elizabeth Anderson - Evercore ISI Eric Percher - Nephron Research Daniel Grosslight - Citibank Allen Lutz - Bank of America George Hill - Deutsche Bank Andrea Alfonso - UBS Charles Rhyee - TD Cowen Erin Wright - Morgan Stanley Operator Hello, ev ...